• Oncoclínicas posted adjusted EBITDA of R$ 34.3 million in 2Q26, swinging from a loss of R$ 49.2 million in 1Q26.
• Gross revenue fell 25.9% quarter-on-quarter to R$ 1.23 billion, reflecting medication supply dynamics and a restrictive commercial policy.
• Adjusted net loss ex-hospitals widened to R$ 275.3 million from R$ 62.3 million in 1Q26.
• Provision for disallowances and doubtful accounts rose to 6.6% of gross revenue; it included a one-off negative impact of about R$ 72 million.
• Operating expenses were hit by about R$ 184.5 million of one-offs, including R$ 78 million impairment and R$ 76 million in contract-termination penalties.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncoclinicas do Brasil Servicos Medicos SA published the original content used to generate this news brief on August 14, 2026, and is solely responsible for the information contained therein.